Urine-Based Analysis Service for Bladder Cancer
Urine-based liquid biopsy has emerged as a promising approach for the detection, diagnosis, and monitoring of bladder cancer. Alfa Cytology provides comprehensive urine-based analysis services for bladder cancer and assists our customers in achieving their goals.
Urine-based Liquid Biopsy in Bladder Cancer
Bladder cancer is a prevalent urological malignancy worldwide, characterized by genomic instability and a high mutation rate. The current diagnosis of bladder cancer heavily relies on invasive and expensive methods such as cystoscopy.
Fig.1 Urine-derived biomarkers for the diagnosis of bladder cancer. (Wang G., et al. 2023)
However, recent advancements in liquid biopsy, specifically urine-based analysis, have opened up new opportunities for non-invasive detection, monitoring, and therapy evaluation of bladder cancer. Due to the highly heterogeneous nature of bladder cancer, tissue biopsies do not always reflect the full picture of the tumor. Circulating molecules such as cell-free DNA, circulating tumor cells, circulating RNA, proteins, peptides, and exosomes provide a complete picture of primary and metastatic tumors.
Our Services
At Alfa Cytology, we specialize in providing a wide range of urine-based analysis services tailored to meet the specific needs of bladder cancer research. Our services encompass every stage of the research process, from protocol design to project completion.
| Service Options |
Specification |
| Samples Collection |
We recommend timely storage of urine samples at -80°C or below. Moreover, a temperature of 4°C or below should be used for temporary storage or transportation of samples. In addition, ETDA, boric acid, or other preservatives may be added to the samples depending on the purpose of the study. |
| Sample Preparation |
Utilizing over 30 years of sample preparation experience, we have developed a variety of specialized automated and manual tools for enrichment and extraction of circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs), exosomes, cell-free miRNAs, or multiple analytes from urine. |
| Biomarker Analysis |
Exfoliated Tumor Cells |
Proteins |
Genes |
Metabolites |
Extracellular Vesicles |
Cytology
Immunocyt or uCyt+
UroVysion |
NMP22
BTA
Oncuria
ADxBladder |
IGFBP5, HOXA13, MDK, CDK1 and CXCR2 Transcripts
FGFR3, TERT and HRAS Mutations
OTX1， ONECUT2 and TWIST1 Methylation
UPK1B, IGF2, CRH, ANXA10 and ABL1 Transcripts |
Adenosine
Succinate
Lactate |
EV DNA/RNA:
MRNA GALNT1 and LASS2
ICRNA HOTAIR
microRNA miR-21-5p
EV Proteins:
TAC STD2
SERPINA1 and H2B1K
Basigin, integrin β1, integrin a6, MUC1, CD10, CD36, CD44, CD73 and 5T4
EDIL-3 |
| Data Analysis and Interpretation |
We provide our clients with detailed reports and actionable insights, helping you understand the implications of their findings and make informed decisions for further research. |
Our Services Will Help You Achieve the Goals as Follows:
- Non-Invasive Detection and Diagnosis
- Monitoring Disease Progression
- Screening and Early Detection
- Monitoring Treatment Response
- Assessment of Tumor Heterogeneity
Benefits of Urine as a Liquid Biopsy
|
Direct Contact with
Bladder Tumor Cells
|
|
Non-Invasive and Patient-Friendly
|
|
Easily Extracted DNA
|
|
Easily Accessible and Available in Larger Quantities
|
Real-Time and Dynamic Assessment
|
Contact Us
At Alfa Cytology, we understand the importance of reliable and efficient urine-based analysis services for bladder cancer research. For more information about our services, collaboration opportunities, or to discuss your specific project needs, please contact us.
References
- Wang G., Jin W., and et al. Urine-based liquid biopsy in bladder cancer: Opportunities and challenges. Clin. Transl. Disc. 2023, 3: e176.
- Oliveira, M. C. d., Caires, H. R., and et al. Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. Cancers, 2020, 12, 1400.
For research use only. Not intended for any clinical use.
Related Services
